ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021
15 September 2021 - 9:30PM
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a
biotechnology company focused on the discovery and development of
antibody therapeutics targeting toxic oligomers implicated in the
development of neurodegenerative diseases, announced today its
participation in the Second Annual Undruggable Leaders Forum, a
virtual event to be held on September 15-16.
ProMIS Chief Development Officer, Dr. Johanne Kaplan, will be
presenting her talk entitled “Selective Targeting of Misfolded
Pathogenic Proteins in Neurodegenerative Diseases” on Sept.16 at
12:40 PM, EST in the session "The Next Undruggable Leaders".
Attendees will learn how ProMIS Neurosciences are using a
computational modeling platform to generate monoclonal antibodies
selectively targeting conformational epitopes on toxic oligomers of
proteins implicated in the pathogenesis of neurodegenerative
diseases including Alzheimer's disease, amyotrophic lateral
sclerosis (ALS) and Parkinson's disease.Registered attendees can
view the presentation live during the Conference; a recorded
version for attendees will also be available to watch at their
convenience. The following link can be used to learn more about the
Conference and to register as an attendee:
https://www.undruggableleaders.com/register/
About ProMIS NeurosciencesProMIS Neurosciences,
Inc. is a development stage biotechnology company focused on
discovering and developing antibody therapeutics selectively
targeting toxic oligomers implicated in the development and
progression of neurodegenerative diseases, in particular
Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and
Parkinson’s disease (PD). The Company’s proprietary target
discovery engine is based on the use of two complementary
techniques. The Company applies its thermodynamic, computational
discovery platform -ProMIS™ and Collective Coordinates - to predict
novel targets known as Disease Specific Epitopes on the molecular
surface of misfolded proteins. Using this unique approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto, Ontario, with offices in
Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock
Exchange under the symbol PMN, and on the OTCQB Venture Market
under the symbol ARFXF.
Visit us at www.promisneurosciences.com, follow us
on Twitter and LinkedIn
For Investor Relations please contact:Alpine Equity
AdvisorsNicholas Rigopulos, Presidentnick@alpineequityadv.comTel.
617 901-0785
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This
information release contains certain forward-looking information.
Such information involves known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jul 2023 to Jul 2024